| 新型糖尿病治疗药物二肽基肽酶IV抑制药的研究进展 |
| |
| 引用本文： | 周凌云,张毕奎,左笑丛.新型糖尿病治疗药物二肽基肽酶IV抑制药的研究进展[J].中国新药与临床杂志,2010(6). |
| |
| 作者姓名： | 周凌云 张毕奎 左笑丛 |
| |
| 作者单位： | 中南大学湘雅三医院药剂科;中南大学药学院; |
| |
| 摘 要： | 二肽基肽酶IV(DPP-IV)抑制药是治疗2型糖尿病的一类新型口服降糖药。DPP-IV抑制药能抑制DDP-IV活性,从而减少胰高糖素样肽1(GLP-1)、葡萄糖依赖性促胰岛素肽(GIP)等的降解,并在GLP-1及GIP的作用下,促进胰岛素的分泌,在有效降低血糖的同时还具有保护胰岛β细胞的功能。本文就该类药物的研究现状及应用前景进行综述。
|
| 关 键 词： | 糖尿病 2型 肠抑胃肽 抗原 CD26 二肽基肽酶类 |
Advances of dipeptidyl peptidase IV inhibitors in diabetes mellitus |
| |
| ZHOU Ling-yun,ZHANG Bi-kui,ZUO Xiao-cong.Advances of dipeptidyl peptidase IV inhibitors in diabetes mellitus[J].Chinese Journal of New Drugs and Clinical Remedies,2010(6). |
| |
| Authors: | ZHOU Ling-yun ZHANG Bi-kui ZUO Xiao-cong |
| |
| Institution: | ZHOU Ling-yun1,2,ZHANG Bi-kui1,ZUO Xiao-cong1(1.Department of Pharmacy,the Third Xiangya Hospital,Central South University,Changsha HU-NAN 410013,China,2.School of Pharmaceutical Science,China) |
| |
| Abstract: | Dipeptidyl peptidase IV(DPP-IV) inhibitor is a new type of oral hypoglycemic agents for the treatment of patients with type 2 diabetes.Inhibition of the enzyme DPP-IV results in decreased degradation of both glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic peptide(GIP).Through the action of GLP-1 and GIP,DPP-IV inhibitors can enhance insulin secretion,control the blood glucose level and protect the function of β-cell.This article reviews the research status and future therapeutic potential of this new type of drug. |
| |
| Keywords: | diabetes mellitus type 2 gastric inhibitory polypeptide antigens CD26 dipeptidyl peptidases |
| 本文献已被 CNKI 等数据库收录！ |
|
